ISIKOK-19 / Acibadem Healthcare, Acibadem University - LARVOL DELTA

Donor-derived CD19 CAR-T Cells (EBMT-EHA 2024) - P1/2 | "Although these limited data make it impossible to compare with autologous CAR T cells, our preliminary data show that donor-derived ISIKOK-19 CAR-T cells are a safe and effective option for the therapy of recurrent B-ALL after allogeneic HSCT."

CAR T-Cell Therapy • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Transplantation • CD4 • CD8

ISIKOK-19 CAR T Cell in ALL with Extramedullary Disease (EHA-EBMT-CART 2023) - P1/2 | "Product characterization, in vivo expansion, and persistence of CAR-T were published before (Erdogan et al, 2022).After a cyclophosphamide/fludarabine-containing lymphodepletion regimen, ISIKOK-19 CAR-T therapy was applied in three fractionated doses...P1 and P2 who had grade 2 CRS needed tocilizumab treatment. Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed only in P4 as grade 2 and this patient recovered after dexamethasone treatment. Besides CRS and ICANS, P4 had hemolytic anemia in the 4th month of CAR-T therapy and recovered after daratumumab treatment.CAR-T was still detected in peripheral blood and CSF in P3 and P4 at 5 months and 6 months, subsequently... In conclusion, the administration of ISIKOK-19 CAR-T therapy in this small patient group with EMD achieved safety and efficacy outcomes. These preliminary results make us believe that ISIKOK-19 CAR-T constitutes a potential therapeutic option in such a high unmet medical need."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Leukemia • Lymphoma • Oncology • Pediatrics • CD8

Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application. (PubMed, Turk J Haematol) - No abstract available

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLD AGLUTININ MEDIATED REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA WITH DARATUMUMAB (EBMT 2022) - " A 22 years old male patient received anti CD-19 directed academic CAR-T cell (ISIKOK-19) infusion due to relapsed acute lymphoblastic leukemia following haploidentical stem cell transplantation from his mother.  Cold agglutinin mediated hemolytic anemia post CAR-T cell treatment is a complex entity with lack of evidence based treatment . Anti CD38 monoclonal antibody daratumumab induces rapidly depletion of antibody producing plasma cells and can be an option in steroid, IVIG and Rituximab refractory cold agglutinin mediated autoimmune hemolytic anemia in CAR-T cell patients."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Inflammation • Leukemia • Oncology • Transplantation • CD19